Prescription drugs will be subject to price inflation penalties in the form of manufacturer rebates in Medicare for the first time under provisions in the Build Back Better social spending legislation being fast-tracked in Congress by Democrats.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?